The KMDA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the KMDA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The KMDA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View KMDA Detailed Price Forecast - CNN Money||View KMDA Detailed Summary - Google Finance|
|View KMDA Detailed Summary - Yahoo! Finance||View KMDA Stock Research & Analysis - Zacks.com|
|View KMDA Trends & Analysis - Trade-Ideas||View KMDA Major Holders - Barrons|
|View KMDA Call Transcripts - NASDAQ||View KMDA Breaking News & Analysis - Seeking Alpha|
|View KMDA Annual Report - CompanySpotlight.com||View KMDA OTC Short Report - OTCShortReport.com|
|View KMDA Fundamentals - TradeKing||View KMDA SEC Filings - Bar Chart|
|View Historical Prices for KMDA - The WSJ||View Performance/Total Return for KMDA - Morningstar|
|View the Analyst Estimates for KMDA - MarketWatch||View the Earnings History for KMDA - CNBC|
|View the KMDA Earnings - StockMarketWatch||View KMDA Buy or Sell Recommendations - MacroAxis|
|View the KMDA Bullish Patterns - American Bulls||View KMDA Short Pain Metrics - ShortPainBot.com|
|View KMDA Stock Mentions - StockTwits||View KMDA Stock Mentions - PennyStockTweets|
|View KMDA Stock Mentions - Twitter||View KMDA Investment Forum News - Investor Hub|
|View KMDA Stock Mentions - Yahoo! Message Board||View KMDA Stock Mentions - Seeking Alpha|
|View Insider Transactions for KMDA - SECform4.com||View Insider Transactions for KMDA - Insider Cow|
|View KMDA Major Holdings Summary - CNBC||View Insider Disclosure for KMDA - OTC Markets|
|View Insider Transactions for KMDA - Yahoo! Finance||View Institutional Holdings for KMDA - NASDAQ|
|View KMDA Stock Insight & Charts - FinViz.com||View KMDA Investment Charts - StockCharts.com|
|View KMDA Stock Overview & Charts - BarChart||View KMDA User Generated Charts - Trading View|
Kamada to Present Corporate Overview at the Cantor Fitzgerald Global Healthcare Conference
Posted on Tuesday September 25, 2018
REHOVOT, Israel, Sept. 25, 2018-- Kamada Ltd., a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor ...
Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
Posted on Wednesday September 05, 2018
Kamada Ltd. (the "Company") (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the potential benefit of the Company’s liquid Alpha-1 Antitrypsin (AAT) on liver preservation and transplant rejection prevention. The Company is collaborating with Massachusetts General Hospital (MGH) which is conducting and funding a study being led by James F. Markmann, M.D., Ph.D., Chief, Division of Transplant Surgery, MGH, who is the Claude E. Welch Professor of Surgery at Harvard Medical School.
Kamada Provides Updated Full-Year 2018 Revenue Guidance
Posted on Wednesday August 29, 2018
Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced that, as a result of the recently settled labor strike at its Beit Kama production facility in Israel, part of its 2018 planned product shipments are likely to be delayed and supplied in early 2019. As a result, the Company is revising its full-year 2018 revenue guidance from the previously provided range of $116 million to $120 million to a range of $102 million to $108 million.
Cannabics Pharmaceuticals Inc. Appoints Dr. Estery Giloz-Ran to Its Advisory Board
Posted on Tuesday August 28, 2018
Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, Board of Directors is proud to announce its addition of Dr Giloz-Ran, former manager of Grants Capital Investment, at INTEL Corporation, Israel - to its advisory board. "We are honored to have Dr. Giloz-Ran join our Board of Advisors, her exceptional record in international business management suits us well as our state-of-the-art laboratory comes into operation and we are being approached by potential medical partners to explore joint ventures," said Eyal Ballan, CTO.